Apellis is a global biopharmaceutical company that leverages courageous science, creativity, and compassion to lead the development of therapies that target the complement system. Apellis is committed to addressing the unmet medical needs of patients and eye care professionals worldwide, with the goal of slowing progression of Geographic Atrophy.

Ocular Therapeutix

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our robust product pipeline positions Ocular Therapeutix to become a leader in the ophthalmic space due to our ability to create drug delivery solutions that reduce the complexity and burden of the current standard of care by developing sustained release alternatives. With a focus on advancing our products through to Phase 3 clinical trials, our intention is to develop a commercially viable portfolio to overcome the issues of patient compliance and adherence by providing means of more consistent and reliable drug dosing for better patient outcomes.



Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

For more information about Regeneron, please visit www.Regeneron.com or follow Regeneron on LinkedIn.

Stuart Therapeutics

Stuart Therapeutics (Stuart) is a clinical stage pharmaceutical company focused on the development of a unique synthetic protein designed to target a previously undruggable target in the human body: helical collagen. The company’s platform technology, called PolyColTM (PolyCol), is a series of synthesized amino acid sequences designed to specifically bind to and repair disease-damaged helical collagen in the extracellular matrix and in membranes. These helical collagen structures play an important role in healthy tissues, including the regulation of inflammation, cell growth and proliferation, among many other processes.

Stuart was founded in 2018 to champion a new approach to the treatment of chronic diseases. Each of our founders has been affected directly or indirectly by chronic eye disease, and we have a passion for the pursuit of new and effective solutions for these indications.
Stuart’s areas of interest are Dry Eye Disease, Glaucoma, Dry Age-Related Macular Degeneration and Myopia.


Annexin Pharmaceuticals

Annexin Pharmaceuticals is a publicly listed (NASDAQ/First North, Sweden) clinical biotech advancing ANXV (a human recombinant protein Annexin A5 ) first-in-class biologic with a broad therapeutic potential as well as a protein- drug conjugate ANXV-chemo. IT is based on research from Karolinska Institutet .The Company focuses on ophthalmology ( clinical stage) and immuno-oncology.

Retinal Vein Occlusion is the primary indication in focus. ANXV has a potential for first in line first in class biologic therapy. The mode of action is non-overlapping to the standard of care (anti-VEGF).

ANXV has completed a Phase 1 trial and demonstrated favorable safety and tolerability profile.

The Phase 2a clinical trial in Retinal Vein Occlusion is approved by the FDA and is currently enrolling in the USA.
The CMC process is optimized.

The IP portfolio is strong with the key patents recently issued in major territories.

Annexin management are looking at strategic options that would facilitate long term development of ANXV/ANXV-conjugate.

Annexon Biosciences

Annexon is pioneering a class of new complement medicines for patients with classical complement-mediated disorders of the body, brain and eye. We are conducting ongoing clinical trials in multiple serious autoimmune, neurodegenerative and ophthalmic diseases.

Eluminex Biosciences

Clinical stage, privately-held (Series B+), bi-coastal biotech (Suzhou BioBAY/Mountain View, CA) focused on the development of advanced protein therapeutics for ophthalmics, regenerative medicine, and dermal/facial aesthetics. EB-105 is lead retina asset and is the world's first true tri-specific fusion antibody targeting VEGF-A/PlGF, Ang-2, and IL-6R for diabetic macular edema. Entering clinic mid-year 2024 (first-in-human) in the United States.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E ™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, EYP-1901, is an investigational sustained delivery.


Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA), and other retinal diseases.

InFocus Clinical Research

At InFocus Clinical Research we are dedicated to advancing the understanding and treatment of retinal diseases. As a leading Contract Research Organization (CRO) with a specialized focus in retina, we provide a range of clinical research services that help our partners accelerate the development of new therapies and technologies. Our team of experts has extensive experience in both clinical trial management and the field of retina research and is committed to providing tailored support services that meet the unique needs of each study. We work closely with our clients to develop customized solutions that optimize trial efficiency, minimize risk, and enhance data quality. Our approach is patient-centered and personalized, with a focus on improving outcomes for those affected by retinal diseases. By leveraging our extensive network of industry contacts and research sites, we help our clients stay at the forefront of the latest developments in retinal research. At InFocus Clinical Research, we are proud to be a trusted partner for our clients, and we are committed to delivering high-quality research solutions that drive innovation and improve the lives of those living with ophthalmic and retinal diseases.

Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase. In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Nanoscope Therapeutics

Nanoscope Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies to cure genetic diseases that cause vision impairment and blindness.
These diseases include Retinitis Pigmentosa, Dry Age-related Macular Degeneration (AMD), and Stargardt Disease. We are developing a proprietary platform technology, employing ambient light-sensitive Multi-Characteristic Opsins (MCO) that has potential to treat a broad range of genetic illnesses.

Neurotech Pharmaceuticals

Neurotech Pharmaceuticals, Inc. is a private clinical stage biotech company focused on developing transformative therapies to slow the progression of Macular Telangiectasia (MacTel) Type 2 and other chronic retinal diseases through its core platform technology, Encapsulated Cell Therapy (ECT). To learn more, visit https://www.neurotechpharmaceuticals.com/.


Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline includes: OCS-01, a topical candidate in Phase 3 for diabetic macular edema and inflammation and pain following ocular surgery; OCS-02, a topical biologic candidate in Phase 2b for dry eye disease and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophthalmic disorders. Headquartered in Switzerland and with operations in the US, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team and supported by leading international healthcare investors.

ONL Therapeutics

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD.


Opthea (Nasdaq: OPT; ASX:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD). Opthea’s lead product candidate OPT-302, is a first-in-class VEGF-C/D ‘trap’ being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone. Opthea has completed a 366-patient Phase 2b clinical trial for the treatment of wet AMD in which OPT-302 administered in combination with the VEGF-A inhibitor Lucentis® (ranibizumab) demonstrated superiority in visual acuity gain compared to Lucentis® administered alone. Opthea is currently recruiting patients into two pivotal Phase 3 clinical trials, ShORe and COAST, with completion of patient recruitment expected as early as December 2023.


REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy has the potential to provide long-lasting effects and improved patient outcomes. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform. We believe this platform forms a strong foundation for our current programs, and with our ongoing research and development, we expect to continue to expand the platform.


RetinAI is a healthcare technology company developing solutions to accelerate decision workflows for pharma and clinics. With improved platforms for harmonizing and aggregating medical data at-scale and advanced analytics of AI, the company improves understanding of patients' disease and outcomes through enhanced knowledge of biomarker-based insights and clinical data.


We are an innovative biopharmaceutical company developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases.

Our mission is to lead the development of mitochondrial medicine to improve the lives of patients with diseases involving mitochondrial dysfunction, an area of high unmet clinical need.

Syneos Health

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.

We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com.